Skip to main content
logo
Intra-Cellular Therapies, Inc. (ITCI)
Apr 2, 2024 - ITCI was delisted (reason: acquired by JNJ)
131.87
0.00 (0.00%)
Inactive · Last trade price on Apr 1, 2025

Intra-Cellular Therapies Stock Forecast

Stock Price Forecast

The 13 analysts with 12-month price forecasts for Intra-Cellular Therapies stock had an average target of $106.75, with a low estimate of $74 and a high estimate of $132.

Price Target: $106.75 (-19.05%)
Analyst Consensus: Buy

Price Target

TargetLowAverageMedianHigh
Price$74$106.75n/a$132
Change-43.88%-19.05%n/a+0.10%

Analyst Ratings

The average analyst rating for Intra-Cellular Therapies stock from 13 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.

Recommendation Trends

No data available
RatingOct 2026
Strong Buyn/a
Buyn/a
Holdn/a
Selln/a
Strong Selln/a
Totaln/a

Financial Forecast

Revenue This Year
966.26M
from 680.85M
Increased by 41.92%
Revenue Next Year
1.57B
from 966.26M
Increased by 62.07%
EPS This Year
0.20
from -0.72
EPS Next Year
4.03
from 0.20
Increased by 1,917.44%
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
22.81M83.80M250.31M464.37M680.85M966.26M1.57B
Revenue Growth
37,537.14%267.35%198.69%85.52%46.62%41.92%62.07%
EPS
-3.23-3.50-2.72-1.46-0.720.204.03
EPS Growth
------1,917.44%
Forward PE
-----660.5932.74
No. Analysts
-----1414

Revenue Forecast

Revenue20252026202720282029
High1.1B1.8B
Avg966.3M1.6B
Low877.5M1.5B

Revenue Growth

Revenue Growth20252026202720282029
High
57.4%
81.2%
Avg
41.9%
62.1%
Low
28.9%
50.2%

EPS Forecast

EPS20252026202720282029
High1.335.63
Avg0.204.03
Low-0.501.95

EPS Growth

EPS Growth20252026202720282029
High-
2,719.3%
Avg-
1,917.4%
Low-
876.9%